Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
1 May 2024
03:21 | Proteinuria diffhist +997 Badgettrg talk contribs (→Diagnosis) |
30 April 2024
|
18:58 | User:AED 4 changes history +85 [Alara E. Dagsali (4×)] | |||
|
18:58 (cur | prev) +20 Alara E. Dagsali talk contribs | ||||
|
18:47 (cur | prev) +22 Alara E. Dagsali talk contribs | ||||
|
18:28 (cur | prev) +20 Alara E. Dagsali talk contribs | ||||
|
18:15 (cur | prev) +23 Alara E. Dagsali talk contribs |
|
N 18:58 | Isosulfan Blue 2 changes history +5,962 [Alara E. Dagsali (2×)] | |||
|
18:58 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
N |
|
18:57 (cur | prev) +5,959 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Lymphazurin |aOrAn=a |indicationType=treatment |indication=Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therape...") |
|
N 18:47 | Ibuprofen Lysine 2 changes history +15,666 [Alara E. Dagsali (2×)] | |||
|
18:47 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
N |
|
18:46 (cur | prev) +15,663 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Ibuprofen lysine |aOrAn=a |indicationType=treatment |indication=Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conduc...") |
|
N 18:28 | Prussian blue 2 changes history +14,070 [Alara E. Dagsali (2×)] | |||
|
18:28 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
N |
|
18:27 (cur | prev) +14,067 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |drugClass=RADIOGARDASE |indicationType=treatment |indication=Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination |adverseReactions=Most common adverse reaction (incidence >24%) was constipation Constipation was reported in 10 (24%) of 42 patients treated with R...") |
|
N 18:15 | Botulism Antitoxin 2 changes history +18,011 [Alara E. Dagsali (2×)] | |||
|
18:15 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
N |
|
18:14 (cur | prev) +18,008 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=BAT |aOrAn=a |indicationType=treatment |indication=BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. |adverseReactions=The most common adverse reactions obse...") |
m 15:35 | Medication reconciliation diffhist +1 Badgettrg talk contribs |
29 April 2024
15:26 | User:AED diffhist +27 Alara E. Dagsali talk contribs |
|
N 15:25 | Trastuzumab emtansine 2 changes history +40,575 [Alara E. Dagsali (2×)] | |||
|
15:25 (cur | prev) −35 Alara E. Dagsali talk contribs | ||||
N |
|
15:23 (cur | prev) +40,610 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=AlaraE.Dagsali |genericName=ado-trastuzumab emtansine |indicationType=treatment |indication=the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. the adjuvant treatment...") |
28 April 2024
m 06:33 | Non-degenerate nucleotides per response element diffhist +207 Marshallsumter talk contribs (→Tabulation of counts) |
27 April 2024
|
m 20:10 | Non-degenerate nucleotides per response element 2 changes history +1,935 [Marshallsumter (2×)] | |||
m |
|
20:10 (cur | prev) +301 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
08:46 (cur | prev) +1,634 Marshallsumter talk contribs (→Tabulation of counts) |
00:49 | Chronic obstructive pulmonary disease history and symptoms diffhist +2,903 Kosar Doraghi talk contribs |
26 April 2024
|
m 20:03 | Non-degenerate nucleotides per response element 2 changes history +2,239 [Marshallsumter (2×)] | |||
m |
|
20:03 (cur | prev) +608 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
08:34 (cur | prev) +1,631 Marshallsumter talk contribs (→Tabulation of counts) |
17:32 | User creation log User account Jonathan Reyes talk contribs was created by Alberto Castro Molina talk contribs |
04:27 | Daprodustat diffhist +1,079 Alen Antony talk contribs |
25 April 2024
22:53 | Reni Syndrome diffhist −3 Alara E. Dagsali talk contribs |
|
N 22:52 | User:AED 3 changes history +3,204 [Alara E. Dagsali (3×)] | |||
|
22:52 (cur | prev) −144 Alara E. Dagsali talk contribs | ||||
|
22:51 (cur | prev) +407 Alara E. Dagsali talk contribs | ||||
N |
|
22:39 (cur | prev) +2,941 Alara E. Dagsali talk contribs (Created page with "==Alara Ece Dagsali== '''Alara Ece Dagsali''' <br>'''Contact:''' email: alaraecedagsai99@gmail.com; +905313614710 ==Medical Education== *School of Medicine (M.D.): Istanbul Medipol University 2021- 2024 Demiroglu Bilim University 2018-2021 ==Pages authored/Co-authored/Collaborated== ===2023=== ====Authored:==== *Reni Syndrome ==Work Experience== *Wikidoc - Associate Editor-In-Chief, 2023 - Current *Yeditepe University Hospitals Cardiac Electrophysiology Lab, Ista...") |
22:48 | Adagrasib diffhist +3 Alara E. Dagsali talk contribs |
22:45 | Norelgestromin diffhist +3 Alara E. Dagsali talk contribs |
|
22:45 | Tranexamic 6 changes history +1 [Alara E. Dagsali (6×)] | |||
|
22:45 (cur | prev) +11 Alara E. Dagsali talk contribs | ||||
|
22:44 (cur | prev) −11 Alara E. Dagsali talk contribs | ||||
|
22:41 (cur | prev) +2 Alara E. Dagsali talk contribs | ||||
|
22:41 (cur | prev) −1 Alara E. Dagsali talk contribs | ||||
|
22:40 (cur | prev) +14 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
|
22:39 (cur | prev) −14 Alara E. Dagsali talk contribs Tag: Manual revert |
22:36 | Alara E. Dagsali diffhist +40 Alara E. Dagsali talk contribs |
|
N 21:21 | Daprodustat 6 changes history +6,894 [Alen Antony (6×)] | |||
|
21:21 (cur | prev) +952 Alen Antony talk contribs | ||||
|
20:53 (cur | prev) +1,266 Alen Antony talk contribs | ||||
|
19:07 (cur | prev) +2,809 Alen Antony talk contribs | ||||
|
17:23 (cur | prev) +563 Alen Antony talk contribs | ||||
|
16:47 (cur | prev) +147 Alen Antony talk contribs | ||||
N |
|
15:23 (cur | prev) +1,157 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=daprodustat |aOrAn=a |drugClass=reversible inhibitor of HIF-PH1, PH2 and PH3. |indicationType=treatment |indication=anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. |hasBlackBoxWarning=Yes |adverseReactions=Hypertension, Abdominal pain, Dizzines, Hypersensitivity, and thrombotic vascular events like Myocardial infarction, stroke, pulmonary embolism,...") |
|
m 17:37 | Non-degenerate nucleotides per response element 2 changes history +3,020 [Marshallsumter (2×)] | |||
m |
|
17:37 (cur | prev) +705 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
07:56 (cur | prev) +2,315 Marshallsumter talk contribs (→Tabulation of counts) |
17:03 | Chronic hypertension medical therapy diffhist +715 Badgettrg talk contribs (→Impact of Blood Pressure self-monitoring in Hypertension Control) |
|
01:50 | Bexagliflozin 4 changes history +3,949 [Alen Antony (4×)] | |||
|
01:50 (cur | prev) +1,145 Alen Antony talk contribs | ||||
|
00:57 (cur | prev) +669 Alen Antony talk contribs | ||||
|
00:50 (cur | prev) +1,349 Alen Antony talk contribs | ||||
|
00:17 (cur | prev) +786 Alen Antony talk contribs |
24 April 2024
|
N 23:35 | Bexagliflozin 4 changes history +1,938 [Alen Antony (4×)] | |||
|
23:35 (cur | prev) +245 Alen Antony talk contribs | ||||
|
23:11 (cur | prev) +1,453 Alen Antony talk contribs | ||||
|
22:55 (cur | prev) +164 Alen Antony talk contribs | ||||
N |
|
21:06 (cur | prev) +76 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=bexagliflozin }}") |
23:17 | Endocarditis overview diffhist +5,051 Kosar Doraghi talk contribs |
|
23:04 | (Upload log) [Kosar Doraghi (2×)] | |||
|
23:04 Kosar Doraghi talk contribs uploaded File:IMG 1177.jpeg | ||||
|
22:59 Kosar Doraghi talk contribs uploaded File:IMG 1176.jpeg |
|
m 23:02 | Non-degenerate nucleotides per response element 3 changes history +3,863 [Marshallsumter (3×)] | |||
m |
|
23:02 (cur | prev) +2,787 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
19:16 (cur | prev) +570 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
06:39 (cur | prev) +506 Marshallsumter talk contribs (→Tabulation of counts) |
|
N 21:26 | Tranexamic 7 changes history +23,022 [Alara E. Dagsali (7×)] | |||
|
21:26 (cur | prev) +14 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
|
21:26 (cur | prev) −11 Alara E. Dagsali talk contribs | ||||
|
21:25 (cur | prev) −2 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
|
21:23 (cur | prev) −1 Alara E. Dagsali talk contribs | ||||
|
21:23 (cur | prev) +3 Alara E. Dagsali talk contribs Tag: Visual edit: Switched | ||||
|
21:22 (cur | prev) −1 Alara E. Dagsali talk contribs | ||||
N |
|
21:14 (cur | prev) +23,020 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Tranexamic |aOrAn=a |drugClass=hemophilia drug |indicationType=prevention |indication=Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. |adverseReactions=Thromboembolic Risk Seizures Hypersensitivity Reactions Visual Disturbances Dizzines...") |
|
N 21:25 | Template:AlaraE.Dagsali 2 changes history +74 [Alara E. Dagsali (2×)] | |||
|
21:25 (cur | prev) −14 Alara E. Dagsali talk contribs | ||||
N |
|
21:21 (cur | prev) +88 Alara E. Dagsali talk contribs (Created page with " Alara Ece Dagsali, M.D.[mailto:alaraecedagsali99@gmail.com]") |
18:12 | Hospital readmissions diffhist +640 Badgettrg talk contribs (→Adults) |
|
07:55 | SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY 2 changes history +2,023 [Hafiza Amna Qadeer (2×)] | |||
|
07:55 (cur | prev) +965 Hafiza Amna Qadeer talk contribs | ||||
|
07:52 (cur | prev) +1,058 Hafiza Amna Qadeer talk contribs (added clinical features) Tag: Visual edit |